United States - English - NLM (National Library of Medicine)

rebel distributors corp - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 10 mg - when used in pregnancy during the second and third trimesters, ace inhibitors can cause injury and even death to the developing fetus. when pregnancy is detected, enalapril maleate/hydrochlorothiazide tablets should be discontinued as soon as possible. see warnings, pregnancy, enalapril maleate, fetal/neonatal morbidity and mortality. enalapril maleate/hydrochlorothiazide is indicated for the treatment of hypertension. these fixed dose combinations are not indicated for initial treatment (see dosage and administration ). in using enalapril maleate/hydrochlorothiazide, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk. (see warnings .) in considering use of enalapril maleate/hydrochlorothiazide, it should be noted that black patients receiving ace inhibitors h

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - enalapril maleate, quantity: 20 mg; hydrochlorothiazide, quantity: 6 mg - tablet, uncoated - excipient ingredients: magnesium stearate; sodium bicarbonate; maize starch; lactose monohydrate; purified talc - mild to moderate hypertension. treatment should not be initiated with this fixed dose combination.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - enalapril maleate, quantity: 20 mg - tablet, uncoated - excipient ingredients: maize starch; sodium bicarbonate; lactose monohydrate; iron oxide red; iron oxide yellow; magnesium stearate; purified talc - indications: hypertension. all grades of essential hypertension; renovascular hypertension. congestive heart failure. treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril sandoz be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence of severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - enalapril maleate, quantity: 10 mg - tablet, uncoated - excipient ingredients: maize starch; sodium bicarbonate; lactose monohydrate; iron oxide red; purified talc; magnesium stearate - indications: hypertension. all grades of essential hypertension; renovascular hypertension. congestive heart failure. treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril sandoz be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - enalapril maleate, quantity: 5 mg - tablet, uncoated - excipient ingredients: maize starch; sodium bicarbonate; lactose monohydrate; hyprolose; purified talc; magnesium stearate - indications: hypertension. all grades of essential hypertension; renovascular hypertension. congestive heart failure. treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril sandoz be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

United States - English - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 mg - enalapril maleate and hydrochlorothiazide tablets, usp are indicated for the treatment of hypertension. these fixed dose combinations are not indicated for initial treatment (see dosage and administration ). in using enalapril maleate and hydrochlorothiazide tablets, usp, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings ). in considering use of enalapril maleate and hydrochlorothiazide tablets, usp, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings , head and neck angioedema ). enalapril maleate and hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - enalapril maleate (unii: 9o25354epj) (enalapril - unii:69pn84io1a), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 g - enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. these fixed dose combinations are not indicated for initial treatment (see dosage and administration). in using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings). in considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings: angioedema ). enalapril maleate and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories limited - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 mg - enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. these fixed dose combinations are not indicated for initial treatment (see dosage and administration ). in using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings ). in considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings, head and neck angioedema ). enalapril maleate and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angi

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 mg - enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial treatment (see dosage and administration). in using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings). in considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings: head and neck angioedema). enalapril maleate and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema

United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - enalapril maleate 5 mg - enalapril maleate and hydrochlorothiazide is indicated for the treatment of hypertension. this fixed dose combination is not indicated for initial treatment (see dosage and administration ). in using enalapril maleate and hydrochlorothiazide, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see warnings ). in considering use of enalapril maleate and hydrochlorothiazide, it should be noted that black patients receiving ace inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see warnings, head and neck angioedema ). enalapril maleate and hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs. enalapril maleate and hydrochlorothiazide is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer enalapril maleate and hydrochlorothiazide within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see warnings ). do not co-administer aliskiren with enalapril maleate and hydrochlorothiazide in patients with diabetes (see precautions, drug interactions ).